A 12-Month Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, and Effectiveness of SEP-4199 Controlled Release (CR) for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression)
Latest Information Update: 26 Feb 2025
At a glance
- Drugs SEP 4199 (Primary)
- Indications Bipolar I disorders
- Focus Adverse reactions; Registrational
- Acronyms RELEASE 3
- Sponsors Sumitomo Pharma America; Sunovion Pharmaceuticals
Most Recent Events
- 01 Dec 2023 Status changed from recruiting to discontinued.
- 18 Mar 2022 Planned End Date changed from 31 May 2026 to 31 May 2029.
- 18 Mar 2022 Planned primary completion date changed from 31 May 2026 to 31 May 2029.